Lauren M. Andring

Lauren M. Andring

Auto-generated profile, based on publicly available information

Lauren M. Andring

Department of Radiation Oncology

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MRMichael Rooney
Michael Rooney
LALauren M. Andring
Lauren M. Andring
KCKelsey L. Corrigan
Kelsey L. Corrigan
VBVincent Bernard
Vincent Bernard
TWTyler D. Williamson
Tyler D. Williamson
SFSteven J Frank
Steven J Frank
(1) Background: Radiotherapy (RT) is a central component for the treatment of many head and neck cancers. In this systematic review of the literature, we aimed to characterize and quantify the published evidence on RT-related hypothyroidism, including estimated incidence, clinical risk factors, and dosimetric parameters that may be used to guide clinical decision making. Furthermore, we aimed to identify potential areas of improvement in the prevention and clinical management of RT-induced hypothyroidism, including the role of modern advanced therapeutic techniques. (2) Methods: We conducted a systemic review of the literature in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. PubMed and Google Scholar were searched to identify original research articles describing the incidence, mechanism, dosimetry, treatment, or prevention of radiation-related hypothyroidism for adults receiving RT for the treatment of head and neck cancers. The snowball method was used to identify additional articles. For identified articles, we tabulated several datapoints, including publication date, patient sample size, estimated hypothyroidism incidence, cancer site/type, follow-up period, radiation modality and technique, use of multimodality therapy, method of thyroid function evaluation, and proposed dosimetric predictors of hypothyroidism. (3) Results: One hundred and eleven articles met inclusion criteria, reflecting a range of head and neck cancer subtypes. There was a large variation in the estimated incidence of RT-related hypothyroidism, with a median estimate of 36% (range 3% to 79%). Reported incidence increased in later publication dates, which was likely related to improved screening and longer follow up. There were a wide variety of predictive metrics used to identify patients at high risk of hypothyroidism, the most common of which were volumetric and mean dosimetrics related to the thyroid gland (Vxx%, Dmean). More recently, there has been increasing evidence to suggest that the thyroid gland volume itself and the volume of the thyroid gland spared from high-dose radiation (VSxx) may better predict thyroid function after RT. There were no identified studies investigating the role of advanced radiotherapeutic techniques such as MRI-guided RT or particle therapy to decrease RT-related hypothyroidism. Conclusions: Hypothyroidism is a common toxicity resulting from therapeutic radiation for head and neck cancer with recent estimates suggesting 40–50% of patients may experience hypothyroidism after treatment. Dosimetric predictive models are increasingly able to accurately identify patients at risk of hypothyroidism, especially those utilizing thyroid VS metrics. Further investigation regarding the potential for advanced radiotherapeutic therapies to decrease RT-induced thyroid dysfunction is needed.

1 January 2022 in Brachytherapy
Verified
Journal Article
Closed access
LALauren Andring
Lauren Andring
AYAlison Yoder
Alison Yoder
TPTodd Pezzi
Todd Pezzi
CTChad Tang
Chad Tang
RKRachit Kumar
Rachit Kumar
GWGary V. Walker
Gary V. Walker

19 April 2021 in International Journal of Neuroscience
Verified
Journal Article
Closed access
LALauren Andring
Lauren Andring
BSBryan Squires
Bryan Squires
ZSZachary Seymour
Zachary Seymour
DFDaniel Fahim
Daniel Fahim
JJJeffrey Jacob
Jeffrey Jacob
IGInga Grills
Inga Grills
Objectives: Limited data exist regarding radionecrosis(RN) rates when patients receive immunotherapy(IT) and SRS for brain metastases. This study assesses the influence of such treatments on the rate of RN. Methods: We retrospectively reviewed 352 lesions from 105 patients with metastatic melanoma or NSCLC treated with SRS and IT from 2012-2018. Lesions were excluded from analysis if patients had received WBRT or prior GK to the same lesion, if RN occurred before IT, or if IT had been discontinued >6 months pre-SRS or initiated >1 year post-SRS. IT was delivered concurrently (+/-30 days of SRS) or sequentially. Overall survival and RN rates were assessed with Kaplan-Meier analysis. Univariate analysis and multivariate analysis were performed to identify characteristics predicting RN. Results: Of 195 lesions from 63 patients included in analysis, the median prescription dose, IDL, lesion volume, and maximum tumor dimension(MTD) were 19 Gy, 50%, 0.15cc and 0.8cm, respectively. RN rates at 1, 2, and 3 years were 7.3%, 10.4% and 10.4%. On UVA, RN risk increased with, isodose volume(IDV), MTD, and tumor volume(TV) whereas conformity index was associated with a trend toward decreased RN risk. Two-year RN rates increased with TV ≥0.3cc (16% vs 1.1% p = 0.001), MTD ≥1.3cm (19.1% vs 1.8% p < 0.003), and IDV ≥1.5cc (19.6% vs 1.7% p = 0.001). Concurrent vs sequential timing of IT did not predict for RN. Conclusions: Patients who received IT and SRS had acceptably low rates of RN. Timing of IT did not predict for RN. Further investigation is warranted to define RN risk with combined SRS and IT.

4 March 2022 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
LALauren M. Andring
Lauren M. Andring
KDKevin Diao
Kevin Diao
SSSusie Sun
Susie Sun
MPMiral Patel
Miral Patel
GWGary J. Whitman
Gary J. Whitman
WWWendy A. Woodward
Wendy A. Woodward

1 August 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
KCKelsey L. Corrigan
Kelsey L. Corrigan
BRBryce B Reeve
Bryce B Reeve
JSJohn M. Salsman
John M. Salsman
ESElizabeth J. Siembida
Elizabeth J. Siembida
GSGrace Smith
Grace Smith
MRMichael Roth
Michael Roth
PURPOSE: Radiation therapy (RT) may cause toxicities in adolescents and young adults (AYAs, age 15-39 years) with cancer. However, the range of RT-related toxicities in AYAs and the affect on health-related quality of life (HRQOL) has not been well studied. We performed a cross-sectional study in AYAs with cancer who received RT to identify RT-related toxicities and examine their impact on HRQOL. MATERIALS AND METHODS: A total of 178 AYAs received RT and completed PROMIS HRQOL instruments from 2018 to 2022. Acute and late physician-graded Common Terminology Criteria for Adverse Events RT–related toxicities were extracted and described. Multivariable linear regression was used to evaluate the association of RT-related toxicity with HRQOL scores during and post-RT. Minimally important differences were used to evaluate the clinical relevance of relationships. RESULTS: Eighty-four AYAs completed HRQOL surveys during RT and 94 post-RT. In the during-RT cohort, 75 AYAs (89%) had acute RT-related toxicities, a majority of which were grade 1 (n = 49, 65%). AYAs who experienced acute grade 2 or greater toxicities reported worse global mental health ( B = –7.35, P < .01) and worse pain ( B = 5.25, P = .01) than those with acute grade 1 or no toxicities. In the post-RT cohort, the median (IQR) time from RT to survey completion was 24 (14-27) months. Forty-eight AYAs (51%) had late RT-related toxicities, a majority of which were grade 1 (n = 37, 77%). AYAs who experienced late grade 2 or greater toxicities reported worse global mental health ( B = –8.07, P = .01), worse social roles ( B = –9.96, P < .01), and greater sleep disturbance ( B = 10.75, P < .01) than those with late grade 1 or no RT toxicities. CONCLUSION: The presence of acute and late grade 2 or greater RT-related toxicities may contribute to worse HRQOL, especially global mental health, in AYAs. Screening and early interventions to mitigate RT-related toxicities are needed to improve AYA HRQOL.

24 March 2023 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
KCKelsey L. Corrigan
Kelsey L. Corrigan
BRBryce B Reeve
Bryce B Reeve
JSJohn M. Salsman
John M. Salsman
ESElizabeth J. Siembida
Elizabeth J. Siembida
LALauren M. Andring
Lauren M. Andring
MRMichael Roth
Michael Roth